Tilray Brands (TLRY): Cannabis & Craft Beer Expansion

Tilray Brands Inc. (NASDAQ: TLRY) (TLRY ) is a global cannabis and consumer packaged goods (CPG) company headquartered in Canada. Following its 2021 merger with Aphria Inc., Tilray became one of Canada’s largest licensed producers (LPs) and one of the most diversified players in the cannabis-adjacent space.

Tilray operates across multiple sectors: recreational and medical cannabis in legal jurisdictions like Canada and parts of Europe; U.S.-based alcoholic beverage production and distribution; and a hemp wellness business through Manitoba Harvest. This multi-category strategy allows the company to remain legally compliant with U.S. federal restrictions while positioning for future cannabis market entry.

Though Tilray cannot sell cannabis in the United States due to federal law, it has made strategic investments in non-plant-touching industries that could serve as platforms for THC products if federal legalization occurs.

Cannabis Market Position

In Canada, Tilray is consistently ranked among the top three licensed cannabis producers by retail market share. Its cannabis brand portfolio includes Good Supply, RIFF, Solei, and Broken Coast on the recreational side, and Tilray Medical for its direct-to-patient offerings.

Internationally, Tilray is one of a handful of companies with EU-GMP certified cannabis facilities in Portugal and Germany. This enables it to export medical cannabis to regulated markets in the European Union, Israel, and Latin America. Tilray has publicly highlighted international expansion, especially in the medical space, as a long-term growth vector.

In the United States, Tilray has built a sizable presence in the craft beer space, owning brands such as SweetWater Brewing Company, Montauk Brewing, Alpine Beer Co., and Green Flash Brewing. In 2024, it significantly expanded its portfolio by acquiring Shock Top, Hop Valley, Terrapin, Revolver, and Atwater from major players AB InBev and Molson Coors.

Tilray’s U.S. operations make it the fifth-largest craft beer company in the country by volume, based on 2024 data. These acquisitions offer both revenue diversification and potential THC beverage distribution infrastructure if federal law changes.

Through Manitoba Harvest, Tilray also leads the U.S. hemp foods category, holding over 50% market share, and has recently expanded into hemp-derived THC beverages, available in select states under compliant legal frameworks.

Financial Performance & Strategy

Tilray reported fiscal 2025 net revenue of $821 million, with strong performance in its beverage-alcohol and international cannabis segments. Despite growing revenue, Tilray posted a net loss of $2.18 billion, driven primarily by non-cash impairment charges. On an adjusted basis, however, Tilray reported $55 million in adjusted EBITDA and $9 million in adjusted net income.

Tilray has been executing a cost-savings strategy across its Canadian cannabis operations, closing underperforming facilities and trimming product SKUs to boost gross margins. Cannabis gross margins improved to approximately 44%, while beverage-alcohol margins ranged from 38% to 53%, depending on the brand and production scale.

The company also began state-by-state distribution of hemp-derived THC beverages in the U.S., generating early revenue (~$1.4 million as of mid-2025) and establishing branding for future federally compliant THC-infused drinks.

Recent Developments

Tilray has been actively restructuring and acquiring over the past 18 months to solidify its diversified growth strategy:

• Acquired craft beer brands Shock Top, Hop Valley, Terrapin, Revolver, and Atwater from AB InBev and Molson Coors in 2024.
• Reached fifth place in U.S. craft beer production volume, according to Brewers Association rankings.
• Launched CBD and THC-infused hemp beverages in multiple U.S. states where compliant.
• Increased focus on international medical cannabis shipments, particularly to Germany and Poland, with European cannabis revenue up 71% year-over-year in Q4 FY25.
• Continued reductions in operating expenses and Canadian cannabis footprint to align with evolving consumer demand and wholesale pricing pressures.

These moves reflect Tilray’s emphasis on diversification, regulatory navigation, and long-term asset positioning for an evolving global cannabis industry.

Investing Potential

Tilray offers investors a rare blend of cannabis exposure, international reach, and U.S. beverage CPG presence, though with both risks and opportunities. Tilray’s investment appeal stems from its diversified portfolio and global footprint. With cannabis operations in federally legal markets and EU-GMP-certified facilities enabling exports, the company maintains international reach. Its U.S. position as the fifth-largest craft brewer provides a potential distribution backbone for future cannabis beverages, while its leadership in hemp wellness supports broad consumer exposure. Ongoing margin improvements and a focus on adjusted profitability further strengthen Tilray’s position as a cannabis-adjacent CPG contender.

Risks:

• GAAP net losses remain significant, driven by asset write-downs and structural inefficiencies.
• Canadian cannabis market remains oversupplied and price pressured.
• Federal cannabis reform in the U.S. remains uncertain, delaying the realization of full cross-border synergy.

Tilray’s performance will likely depend on its ability to continue growing high-margin segments, execute operational efficiencies, and time U.S. federal reform effectively to capitalize on its beverage infrastructure.

Latest TLRY (TLRY) Stock News and Developments

Error fetching company profile. Check if the symbol is valid.

Final Thoughts

Tilray Brands is one of the most visible and diversified public companies in the cannabis-adjacent investment landscape. With cannabis production in Canada and Europe, a growing share of the U.S. craft beer market, and a presence in the hemp wellness sector, Tilray offers a multi-pronged approach to navigating regulatory restrictions.

While profitability has proven elusive under GAAP, the company’s adjusted EBITDA growth, beverage revenue increases, and international medical expansion reflect a business evolving beyond just Canadian flower.

Tilray may not be a pure cannabis play, but its infrastructure, branding, and regulatory foresight make it a company worth watching in both the CPG and cannabis evolution narratives.